NOS inhibition modulates immune polarization and improves radiation-induced tumor growth delay

Cancer Research

Volumn 75, Issue 14, 2015, Pages 2788-2799

  Ridnour, Lisa A ^a   Cheng, Robert Y S ^a   Weiss, Jonathan M ^b   Kaur, Sukhbir ^a   Soto Pantoja, David R ^a   Basudhar, Debashree ^a   Heinecke, Julie L ^a   Stewart, C Andrew ^b   DeGraff, William ^a   Sowers, Anastasia L ^a   Thetford, Angela ^a   Kesarwala, Aparna H ^a   Roberts, David D ^a   Young, Howard A ^b   Mitchell, James B ^a   Trinchieri, Giorgio ^b   Wiltrout, Robert H ^b   Wink, David A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 2; MORPHOLINO OLIGONUCLEOTIDE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; THROMBOSPONDIN 1; ENZYME INHIBITOR; RADIOSENSITIZING AGENT;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER RADIOTHERAPY; CD8+ T LYMPHOCYTE; CELL GROWTH; CELL POLARITY; CONTROLLED STUDY; DISEASE COURSE; DRUG TARGETING; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMMUNE SYSTEM; IMMUNOMODULATION; IN VIVO STUDY; IONIZING RADIATION; JURKAT CELL LINE; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION RESPONSE; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; TH1 CELL; TH2 CELL; TUMOR CELL; TUMOR GROWTH DELAY; WOUND; WOUND HEALING; ANIMAL; ANTAGONISTS AND INHIBITORS; C3H MOUSE; C57BL MOUSE; CELL PROLIFERATION; DRUG EFFECTS; FEMALE; KNOCKOUT MOUSE; LYMPHOCYTE ACTIVATION; NEOPLASMS; NEUTROPHIL CHEMOTAXIS; NUDE MOUSE; PATHOLOGY; RADIATION DOSE;

ANIMALS; CELL PROLIFERATION; CHEMOTAXIS, LEUKOCYTE; ENZYME INHIBITORS; FEMALE; HUMANS; JURKAT CELLS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, NUDE; NEOPLASMS; NITRIC OXIDE SYNTHASE; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS;

EID: 84942902688     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-3011     Document Type: Article

References (60)

1. El Kaffas A, Tran W, Czarnota GJ. Vascular strategies for enhancing tumour response to radiation therapy. Technol Cancer Res Treat 2012; 11: 421-32.
2. Bernier J, Hall EJ, Giaccia A. Radiation oncology: a century of achievements. Nat Rev Cancer 2004; 4: 737-47.
3. Kargiotis O, Geka A, Rao JS, Kyritsis AP. Effects of irradiation on tumor cell survival, invasion and angiogenesis. J Neurooncol 2010; 100: 323-38.
4. Bergers G, Hanahan D. Modes of resistance toanti-angiogenic therapy. Nat Rev Cancer 2008; 8: 592-603.
5. Prise KM, Schettino G, Folkard M, Held KD. New insights on cell death from radiation exposure. Lancet Oncol 2005; 6: 520-8.
6. Ridnour LA, Barasch KM, Windhausen AN, Dorsey TH, Lizardo MM, Yfantis HG, et al. Nitric oxide synthase and breast cancer: role of TIMP-1 in NO-mediated Akt activation. PLoS One 2012; 7: e44081.
7. Switzer CH, Glynn SA, Cheng RY, Ridnour LA, Green JE, Ambs S, et al. S-Nitrosylation of EGFR and Src activates an oncogenic signaling networkinhuman basal-like breast cancer. Mol Cancer Res 2012; 10: 1203-15.
8. Switzer CH, Cheng RY, Ridnour LA, Glynn SA, Ambs S, Wink DA. Ets-1 is a transcriptional mediator of oncogenic nitric oxide signaling in estrogen receptor-negative breast cancer. Breast Cancer Res 2012; 14: R125.
9. Glynn SA, Boersma BJ, Dorsey TH, Yi M, Yfantis HG, Ridnour LA, et al. Increased NOS2 predicts poor survival in estrogen receptor-negative breast cancer patients. J Clin Invest 2010; 120: 3843-54.
10. Knowles RG, Moncada S. Nitric oxide synthases in mammals. Biochem J 1994; 298 (Pt 2): 249-58.
11. Ridnour LA, Thomas DD, Donzelli S, Espey MG, Roberts DD, Wink DA, et al. The biphasic nature of nitric oxide responses in tumor biology. Antioxid Redox Signal 2006; 8: 1329-37.
12. Heinecke JL, Ridnour LA, Cheng RY, Switzer CH, Lizardo MM, Khanna C, et al. Tumor microenvironment-based feed-forward regulation of NOS2 in breast cancer progression. Proc Natl Acad Sci U S A 2014; 111: 6323-8.
13. Ekmekcioglu S, Ellerhorst J, Smid CM, Prieto VG, Munsell M, Buzaid AC, et al. Inducible nitric oxide synthase and nitrotyrosine in human metastatic melanoma tumors correlate with poor survival. Clin Cancer Res 2000; 6: 4768-75.
14. Zhang W, He XJ, Ma YY, Wang HJ, Xia YJ, Zhao ZS, et al. Inducible nitric oxide synthase expression correlates with angiogenesis, lymphangiogenesis, and poor prognosis in gastric cancer patients. Hum Pathol 2011; 42: 1275-82.
15. Eyler CE, Wu Q, Yan K, MacSwords JM, Chandler-Militello D, Misuraca KL, et al. Glioma stem cell proliferation and tumor growth are promoted by nitric oxide synthase-2. Cell 2011; 146: 53-66.
16. Papapetropoulos A, Garcia-Cardena G, Madri JA, Sessa WC. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J Clin Invest 1997; 100: 3131-9.
17. Ng QS, Goh V, Milner J, Stratford MR, Folkes LK, Tozer GM, et al. Effect of nitric-oxide synthesis on tumour blood volume and vascular activity: a phase I study. Lancet Oncol 2007; 8: 111-8.
18. Cuneo KC, Geng L, Fu A, Orton D, Hallahan DE, Chakravarthy AB. SU11248 (sunitinib) sensitizes pancreatic cancer to the cytotoxic effects of ionizing radiation. Int J Radiat Oncol Biol Phys 2008; 71: 873-9.
19. Leach JK, Black SM, Schmidt-Ullrich RK, Mikkelsen RB. Activation of constitutive nitric-oxide synthase activity is an early signaling event induced by ionizing radiation. J Biol Chem 2002; 277: 15400-6.
20. Cardnell RJ, Mikkelsen RB. Nitric oxide synthase inhibition enhances the antitumor effect of radiation in the treatment of squamous carcinoma xenografts. PLoS One 2011; 6: e20147.
21. Roses RE, Datta J, Czerniecki BJ. Radiation as immunomodulator: implications for dendritic cell-based immunotherapy. Radiat Res 2014; 182: 211-8.
22. Ganss R, Ryschich E, Klar E, Arnold B, Hammerling GJ. Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. Cancer Res 2002; 62: 1462-70.
23. Kaur P, Asea A. Radiation-induced effects and the immune system in cancer. Front Oncol 2012; 2: 191.
24. Facciabene A, Motz GT, Coukos G. T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res 2012; 72: 2162-71.
25. Strauss L, Bergmann C, Szczepanski M, Gooding W, Johnson JT, Whiteside TL. A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-b1 mediates suppression in the tumor microenvironment. Clin Cancer Res 2007; 13: 4345-54.
26. Niedbala W, Wei XQ, Campbell C, Thomson D, Komai-Koma M, Liew FY. Nitric oxide preferentially induces type 1Tcell differentiation by selectively up-regulating IL-12 receptor b2 expression via cGMP. Proc Natl Acad Sci U S A 2002; 99: 16186-91.
27. +CD25 T cells via p53, IL-2, and OX40. Proc Natl Acad Sci U S A 2007; 104: 15478-83.
28. Davies KM, Wink DA, Saavedra JE, Keefer LK. Chemistry of the diazenium-diolates. 2. Kinetics and mechanism of dissociation to nitric oxide in aqueous solution. J Am Chem Soc 2001; 123: 5473-81.
29. Cox GW, Mathieson BJ, Gandino L, Blasi E, Radzioch D, Varesio L. Heterogeneity of hematopoietic cells immortalized by v-myc/v-raf recombinant retrovirus infection of bone marrow or fetal liver. J Natl Cancer Inst 1989; 81: 1492-6.
30. Chou MI, Hsieh YF, Wang M, Chang JT, Chang D, Zouali M, et al. In vitro and in vivo targeted delivery of IL-10 interfering RNA by JC virus-like particles. J Biomed Sci 2010; 17: 51-9.
31. Saito K, Matsumoto S, Yasui H, Devasahayam N, Subramanian S, Munasinghe JP, et al. Longitudinal imaging studies of tumor microenvironment in mice treated with the mTOR inhibitor rapamycin. PLoS One 2012; 7: e49456.
32. Rozen S, Skaletsky H. Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 2000; 132: 365-86.
33. Reinhold MI, Green JM, Lindberg FP, Ticchioni M, Brown EJ. Cell spreading distinguishes the mechanism of augmentation of T cell activation by integrin-associated protein/CD47 and CD28. Int Immunol 1999; 11: 707-18.
34. Beccano-Kelly DA, Kuhlmann N, Tatarnikov I, Volta M, Munsie LN, Chou P, et al. Synaptic function is modulated by LRRK2 and glutamate release is increased in cortical neurons of G2019S LRRK2 knock-in mice. Front Cell Neurosci 2014; 8: 301.
35. Boer R, Ulrich WR, Klein T, Mirau B, Haas S, Baur I. The inhibitory potency and selectivity of arginine substrate site nitric-oxide synthase inhibitors is solely determined by their affinity toward the different isoenzymes. Mol Pharmacol 2000; 58: 1026-34.
36. Liao W, Lin JX, Leonard WJ. IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation. Curr Opin Immunol 2011; 23: 598-604.
37. Stout RD, Watkins SK, Suttles J. Functional plasticity of macrophages: in situ reprogramming of tumor-associated macrophages. J Leukoc Biol 2009; 86: 1105-9.
38. Connelly L, Jacobs AT, Palacios-Callender M, Moncada S, Hobbs AJ. Macrophage endothelial nitric-oxide synthase autoregulates cellular activation and pro-inflammatory protein expression. J Biol Chem 2003; 278: 26480-7.
39. Thomas DD, Espey MG, Ridnour LA, Hofseth LJ, Mancardi D, Harris CC, et al. Hypoxic inducible factor 1α, extracellular signal-regulated kinase, and p53 are regulated by distinct threshold concentrations of nitric oxide. Proc Natl Acad Sci U S A 2004; 101: 8894-9.
40. Ridnour LA, Windhausen AN, Isenberg JS, Yeung N, Thomas DD, Vitek MP, et al. Nitric oxide regulates matrix metalloproteinase-9 activity by guanylylcyclase-dependent and -independent pathways. Proc Natl Acad Sci U S A 2007; 104: 16898-903.
41. Ridnour LA, Isenberg JS, Espey MG, Thomas DD, Roberts DD, Wink DA. Nitric oxide regulates angiogenesis through a functional switch involving thrombospondin-1. Proc Natl Acad Sci U S A 2005; 102: 13147-52.
42. Isenberg JS, Ridnour LA, Perruccio EM, Espey MG, Wink DA, Roberts DD. Thrombospondin-1 inhibits endothelial cell responses to nitric oxide in a cGMP-dependent manner. Proc Natl Acad Sci U S A 2005; 102: 13141-6.
43. Zhang YH, Casadei B. Sub-cellular targeting of constitutive NOS in health and disease. J Mol Cell Cardiol 2012; 52: 341-50.
44. Zhao Y, Xiong Z, Lechner EJ, Klenotic PA, Hamburg BJ, Hulver M, et al. Thrombospondin-1 triggers macrophage IL-10 production and promotes resolution of experimental lung injury. Mucosal Immunol 2014; 7: 440-8.
45. Morcos PA, Li Y, Jiang S. Vivo-Morpholinos: a non-peptide transporter delivers Morpholinos into a wide array of mouse tissues. Biotechniques 2008; 45: 613-4, 6, 8 passim.
46. Soto-Pantoja DR, Ridnour LA, Wink DA, Roberts DD. Blockade of CD47 increases survival of mice exposed to lethal total body irradiation. Sci Rep 2013; 3: 1038.
47. Sonveaux P, Brouet A, Havaux X, Gregoire V, Dessy C, Balligand JL, et al. Irradiation-induced angiogenesis through the up-regulation of the nitric oxide pathway: implications for tumor radiotherapy. Cancer Res 2003; 63: 1012-9.
48. Nagane M, Yasui H, Yamamori T, Zhao S, Kuge Y, Tamaki N, et al. Radiation-induced nitric oxide mitigates tumor hypoxia and radioresistance in a murine SCCVII tumor model. Biochem Biophys Res Commun 2013; 437: 420-5.
49. Howard-Flanders P. Effect of nitric oxide on the radiosensitivity of bacteria. Nature 1957; 180: 1191-2.
50. Wardman P, Rothkamm K, Folkes LK, Woodcock M, Johnston PJ. Radiosensitization by nitric oxide at low radiation doses. Radiat Res 2007; 167: 475-84.
51. Coulter JA, McCarthy HO, Worthington J, Robson T, Scott S, Hirst DG. The radiation-inducible pE9 promoter driving inducible nitric oxide synthase radiosensitizes hypoxic tumour cells to radiation. Gene Ther 2008; 15: 495-503.
52. Kashiwagi S, Tsukada K, Xu L, Miyazaki J, Kozin SV, Tyrrell JA, et al. Perivascular nitric oxide gradients normalize tumor vasculature. Nat Med 2008; 14: 255-7.
53. Thoday JM, Read J. Effect of oxygen on the frequency of chromosome aberrations produced by α-rays. Nature 1949; 163: 133-4.
54. Schwentker A, Vodovotz Y, Weller R, Billiar TR. Nitric oxide and wound repair: role of cytokines? Nitric Oxide 2002; 7: 1-10.
55. Yamasaki K, Edington HD, McClosky C, Tzeng E, Lizonova A, Kovesdi I, et al. Reversal of impaired wound repair in iNOS-deficient mice by topical adenoviral-mediated iNOS gene transfer. J Clin Invest 1998; 101: 967-71.
56. Moeller BJ, Cao Y, Li CY, Dewhirst MW. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 2004; 5: 429-41.
57. Bernstein MB, Garnett CT, Zhang H, Velcich A, Wattenberg MM, Gameiro SR, et al. Radiation-induced modulation of costimulatory and coinhibitory T-cell signaling molecules on human prostate carcinoma cells promotes productive antitumor immune interactions. Cancer Biother Radiopharm 2014; 29: 153-61.
58. Gerber SA, Sedlacek AL, Cron KR, Murphy SP, Frelinger JG, Lord EM. IFN-g mediates the antitumor effects of radiation therapy in a murine colon tumor. Am J Pathol 2013; 182: 2345-54.
59. Liao W, Lin JX, Leonard WJ. Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity 2013; 38: 13-25.
60. Nozaki S, Sledge GW Jr, Nakshatri H. Cancer cell-derived interleukin 1α contributes to autocrine and paracrine induction of pro-metastatic genes in breast cancer. Biochem Biophys Res Commun 2000; 275: 60-2.